1. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal Cord 44, 523-529 (2006).
2. Chen Y, Tang Y, Vogel LC, Devivo MJ. Causes of spinal cord injury. Top Spinal Cord Inj Rehabil 19, 1-8 (2013).
3. Cizkova D, et al. Understanding Molecular Pathology along Injured Spinal Cord Axis: Moving Frontiers toward Effective Neuroprotection and Regeneration.
4. Devaux S, et al. Proteomic Analysis of the Spatio-temporal Based Molecular Kinetics of Acute Spinal Cord Injury Identifies a Time- and Segment-specific Window for Effective Tissue Repair. Molecular & cellular proteomics : MCP 15, 2641-2670 (2016).
5. Cizkova D, et al. Alterations of protein composition along the rostro-caudal axis after spinal cord injury: proteomic, in vitro and in vivo analyses. Front Cell Neurosci 8, 105 (2014).
6. Freund P, et al. Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 12, 790-792 (2006).
7. Freund P, et al. Anti-Nogo-A antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates--re-examination and extension of behavioral data. Eur J Neurosci 29, 983-996 (2009).
8. DePaul MA, Lin CY, Silver J, Lee YS. Combinatory repair strategy to promote axon regeneration and functional recovery after chronic spinal cord injury. Scientific reports 7, 9018 (2017).
9. Ulndreaj A, Badner A, Fehlings MG. Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury. F1000Res 6, 1907 (2017).
10. Thibault-Halman G, et al. Predicting Recruitment Feasibility for Acute Spinal Cord Injury Clinical Trials in Canada Using National Registry Data. Journal of neurotrauma 34, 599-606 (2017).
11. Fehlings MG, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. J Neurosurg Spine 17, 151-156 (2012).
12. Devaux S, et al. RhoA Inhibitor Treatment At Acute Phase of Spinal Cord Injury May Induce Neurite Outgrowth and Synaptogenesis. Molecular & cellular proteomics : MCP 16, 1394-1415 (2017).
13. Nguyen VK, Su C, Muyldermans S, van der Loo W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics 54, 39-47 (2002).
14. Leslie M. Small but mighty. Science 360, 594-597 (2018).
15. Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS biology 9, e1001120 (2011).
16. Conrath KE, Wernery U, Muyldermans S, Nguyen VK. Emergence and evolution of functional heavy-chain antibodies in Camelidae. Developmental and comparative immunology 27, 87-103 (2003).
17. Murphy K, Weaver C. Janeway's immunobiology. Garland Science (2016).
18. Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Frontiers in neuroscience 8, 235 (2014).
19. Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. The Journal of pathology 217, 497-506 (2009).
20. Nemeth-Cawley JF, Tangarone BS, Rouse JC. "Top Down" characterization is a complementary technique to peptide sequencing for identifying protein species in complex mixtures. Journal of proteome research 2, 495-505 (2003).
21. Fornelli L, et al. Top-down analysis of immunoglobulin G isotypes 1 and 2 with electron transfer dissociation on a high-field Orbitrap mass spectrometer. Journal of proteomics 159, 67-76 (2017).
22. Pradzinska M, et al. Isolation and characterization of autoantibodies against human cystatin C. Amino acids 48, 2501-2518 (2016).
23. Konno N, et al. Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease. PLoS One 13, e0196163 (2018).
24. Mills JR, Barnidge DR, Murray DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 81, 56-65 (2015).
25. Blanc MR, et al. A one‐step exclusion‐binding procedure for the purification of functional heavy‐chain and mammalian‐type γ‐globulins from camelid sera. Biotechnology and applied biochemistry 54, 207-212 (2009).
26. Scheurer L, et al. Expression of immunoglobulin constant domain genes in neurons of the mouse central nervous system. Life science alliance 4, (2021).
27. Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nature neuroscience 10, 19-26 (2007).
28. Whittemore E, Loo D, Watt J, Cotmans C. A detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture. Neuroscience 67, 921-932 (1995).
29. Aicheler RJ, Wang EC, Tomasec P, Wilkinson GW, Stanton RJ. Potential for natural killer cell-mediated antibody-dependent cellular cytotoxicity for control of human cytomegalovirus. Antibodies 2, 617-635 (2013).
30. Ulvestad E, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 121, 125-131 (1994).
31. Zhang J, Niu N, Li B, McNutt MA. Neuron-derived IgG protects neurons from complement-dependent cytotoxicity. J Histochem Cytochem 61, 869-879 (2013).
32. Lajoie L, et al. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation. The Journal of Immunology 192, 741-751 (2014).
33. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 24, 19-28 (2006).
34. Diamond B, Honig G, Mader S, Brimberg L, Volpe B. Brain-reactive antibodies and disease. Annual review of immunology 31, 345-385 (2013).
35. Nataf S. Autoimmunity as a Driving Force of Cognitive Evolution. Front Neurosci 11, 582 (2017).
36. Nataf S. Evolution, immunity and the emergence of brain superautoantigens. F1000Res 6, 171 (2017).
37. Hansen J, et al. A novel mutation in the HSPD1 gene in a patient with hereditary spastic paraplegia. J Neurol 254, 897-900 (2007).
38. Prineas JW, Parratt JDE. Multiple sclerosis: Serum anti-CNS autoantibodies. Mult Scler, 1352458517706037 (2017).
39. Kobeissy F, Moshourab RA. Autoantibodies in CNS Trauma and Neuropsychiatric Disorders: A New Generation of Biomarkers. In: Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects (ed Kobeissy FH) (2015).
40. Ankeny DP, Guan Z, Popovich PG. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 119, 2990-2999 (2009).
41. Poletaev A, Boura P. The immune system, natural autoantibodies and general homeostasis in health and disease. Hippokratia 15, 295 (2011).
42. Kozlowski GP, Sterzl I, Nilaver G. Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood-brain barrier (BBB). Progress in brain research 91, 149-154 (1992).
43. Aihara N, Tanno H, Hall JJ, Pitts LH, Noble LJ. Immunocytochemical localization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. The Journal of comparative neurology 342, 481-496 (1994).
44. Tanno H, Nockels RP, Pitts LH, Noble LJ. Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: Distribution and time course of protein extravasation. Journal of neurotrauma 9, 21-32 (1992).
45. Kobeissy F, Moshourab RA. Autoantibodies in CNS Trauma and Neuropsychiatric Disorders. (2015).
46. Beseler C, Vollmer T, Graner M, Yu X. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PloS one 12, e0186842 (2017).
47. Wootla B, Denic A, Watzlawik JO, Warrington AE, Rodriguez M. Antibody-mediated oligodendrocyte remyelination promotes axon health in progressive demyelinating disease. Molecular neurobiology 53, 5217-5228 (2016).
48. Bieber AJ, Warrington A, Pease LR, Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends in neurosciences 24, S39-S44 (2001).
49. Mitsunaga Y, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. The FASEB Journal 16, 1325-1327 (2002).
50. Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA. Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proceedings of the National Academy of Sciences 107, 11993-11998 (2010).
51. Wright BR, Warrington AE, Edberg DE, Rodriguez M. Cellular mechanisms of central nervous system repair by natural autoreactive monoclonal antibodies. Archives of neurology 66, 1456-1459 (2009).
52. Schwartz M. "Tissue-repairing" blood-derived macrophages are essential for healing of the injured spinal cord: from skin-activated macrophages to infiltrating blood-derived cells? Brain Behav Immun 24, 1054-1057 (2010).
53. Dey A, et al. neuroprotective role of the ron receptor Tyrosine Kinase Underlying central nervous system inflammation in health and Disease. Frontiers in immunology 9, 513 (2018).
54. Cizkova D, et al. Modulation properties of factors released by bone marrow stromal cells on activated microglia: an in vitro study. Scientific reports 4, 7514 (2014).
55. Ankeny DP, Popovich PG. B cells and autoantibodies: complex roles in CNS injury. Trends Immunol 31, 332-338 (2010).
56. Itoh N, et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. Proceedings of the National Academy of Sciences 115, E302-E309 (2018).